Shots:
- Atara to receive $60M upfront and ~$610M as development, regulatory & commercialization milestones + tiered royalties on net sales. The collaboration focuses on off-the-shelf T-cell immunotherapy ATA3271 and ATA2271
- Atara will lead to IND and process development for ATA3271 and will continue to be responsible for P-I study of ATA2271 while Bayer will be responsible for submitting the IND and subsequent clinical development and commercialization
- Atara will also provide translational & clinical manufacturing services to be reimbursed by Bayer. In addition, for a limited period, Bayer has a non-exclusive right to negotiate a license for additional Atara CAR T product candidates
Click here to read full press release/ article | Ref: Businesswire | Image: Express Pharma
The post Bayer Signs an Exclusive Worldwide License Agreement with Atara for Mesothelin-Targeted CAR T-cell Therapies to Treat Solid Tumors first appeared on PharmaShots.
